Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a securities class action alleging violations of federal securities laws. The claims, as described in multiple law-firm notices, relate to statements about the company’s Phase 3 HOPE-3 results. One allegation is that the company presented the results as statistically significant while allegedly omitting information about final statistical analysis changes made shortly before unblinding and related approval issues.

Several outlets frame the developments through investor “lead plaintiff” reminders, pointing to deadlines and potential eligibility windows. Multiple notices state that investors who bought CAPR during a defined class period can seek to be appointed lead plaintiff, with a lead plaintiff deadline listed as September 28, 2026. Law firms also issue different context and action prompts—such as contacting specific firms or monitoring additional related procedural milestones—while generally describing the same lawsuit.

One additional angle involves FDA-related timing, where an alert references an FDA review extension for deramiocel in the context of the ongoing litigation and the September 28 lead plaintiff deadline. Across sources, the common focus is procedural: who may participate, what the alleged conduct is, and when investors must act.